Ziopharm Oncology, Inc.

Solasia Pharma K.k.

Abbvie Manufacturing Management Unlimited Company

Philip B Komarnitsky

Barbara P Wallner

Brian Schwartz

Jonathan Lewis

John C Amedio, Jr

Janet Yikai Jin

Mirella Lazarov

Anita Reddy

Brian Eric Schwartz

The present disclosure provides improved methods of treatment of NSCLC cancers using telisotuzumab vedotin.

Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin

A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and Rand Rare independently Calkyl (R, R, R, R, W and 'n' are as defined in claim) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol. 

Organoarsenic compounds and methods for the treatment of cancer

Disclosed herein are crystalline compounds of formula (I) 

Salts of isophosphoramide mustard and analogs thereof

Organic arsenical compounds are useful to inhibit angiogenesis in a variety of disease conditions.

Method for controlling angiogenesis in animals

The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.

Growing community of inventors

Chestnut Hill, MA, United States of America

Philip B Komarnitsky